Sign Out
Paracetamol: Barbiturates (eg, phenobarbital): The potential hepatotoxicity of paracetamol may be increased when large or chronic doses of barbiturates are coadministered. The therapeutic effects of paracetamol may be reduced with barbiturate therapy.
Ethanol: Chronic consumption of ethanol may increase the risk of paracetamol-induced liver damage.
Chlorpheniramine maleate: Alcohol, CNS depressants, tricyclic antidepressants: Concurrent use may potentiate the effects of either these medications or antihistamines.
MAO inhibitors: Concurrent use may prolong and intensify the antimuscarinic effects of antihistamines and is generally not recommended.
Ototoxic medications, in particular the ototoxic antibiotics: Concurrent use with antihistamines may mask the symptoms of ototoxicity.
Alcohol, sedatives, and tranquilizers may increase the drowsiness effect. Avoid alcoholic beverages while taking this product. Do not take this product if the patient is taking sedatives or tranquilizers, without first consulting the physician.
Phenylephrine hydrochloride: Monoamine oxidase (MAO) inhibitors: Do not use this product with prescription MAO inhibitors (certain drugs for depression, psychiatric or emotional conditions or Parkinson's disease) or for 2 weeks after stopping the MAO inhibitor drug. If the patient is uncertain whether prescription drugs contain an MAO inhibitor, consult a health professional before giving this product.
Continue with Google